

# Jose-Angel Hernandez-Rivas

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/9360172/publications.pdf>

Version: 2024-02-01

60  
papers

1,932  
citations

361413

20  
h-index

276875

41  
g-index

63  
all docs

63  
docs citations

63  
times ranked

3080  
citing authors

#	ARTICLE	IF	CITATIONS
1	Hypermetabolic abdominal and cervical lymph nodes mimicking Hodgkin lymphoma relapse on FDG PET/CT after adenovirus-vectored COVID-19 vaccine. <i>Human Vaccines and Immunotherapeutics</i> , 2024, 17, 5129-5132.	3.3	10
2	SARS-CoV-2 reactive antibody detection after SARS-CoV-2 vaccination in hematopoietic stem cell transplant recipients: Prospective survey from the Spanish Hematopoietic Stem Cell Transplantation and Cell Therapy Group. <i>American Journal of Hematology</i> , 2022, 97, 30-42.	4.1	52
3	Spanish Society of Hematology and Hemotherapy expert consensus opinion for SARS-CoV-2 vaccination in onco-hematological patients. <i>Leukemia and Lymphoma</i> , 2022, 63, 538-550.	1.3	8
4	COVID-19 in vaccinated adult patients with hematological malignancies: preliminary results from EPICOVIDEHA. <i>Blood</i> , 2022, 139, 1588-1592.	1.4	70
5	The changing landscape of relapsed and/or refractory multiple myeloma (MM): fundamentals and controversies. <i>Biomarker Research</i> , 2022, 10, 1.	6.8	22
6	A simple score to predict early severe infections in patients with newly diagnosed multiple myeloma. <i>Blood Cancer Journal</i> , 2022, 12, 68.	6.2	8
7	TRAF3 alterations are frequent in del(11q) chronic lymphocytic leukemia patients and define a specific subgroup with adverse clinical features. <i>American Journal of Hematology</i> , 2022, 97, 903-914.	4.1	3
8	SARS-CoV-2 vaccine response and rate of breakthrough infection in patients with hematological disorders. <i>Journal of Hematology and Oncology</i> , 2022, 15, 54.	17.0	26
9	IBRORS-MCL study: a Spanish retrospective and observational study of relapsed/refractory mantle-cell lymphoma treated with ibrutinib in routine clinical practice. <i>International Journal of Hematology</i> , 2022, , .	1.6	0
10	Applicability of probabilistic graphical models for early detection of SARS-CoV-2 reactive antibodies after SARS-CoV-2 vaccination in hematological patients. <i>Annals of Hematology</i> , 2022, 101, 2053-2067.	1.8	7
11	Blood transfusion activity in a general hospital during the COVID-19 pandemic. <i>Vox Sanguinis</i> , 2021, 116, 574-580.	1.5	9
12	RCOMP versus RCHOP as first-line therapy for diffuse large B-cell lymphoma in patients $\geq 60$ years: Results of a randomized phase 2 study from the Spanish GELTAMO group. <i>Cancer Medicine</i> , 2021, 10, 1314-1326.	2.8	13
13	Risk Factors and Mortality of COVID-19 in Patients With Lymphoma: A Multicenter Study. <i>HemaSphere</i> , 2021, 5, e538.	2.7	52
14	Dissecting the role of TP53 alterations in del(11q) chronic lymphocytic leukemia. <i>Clinical and Translational Medicine</i> , 2021, 11, e304.	4.0	7
15	Systemic thrombosis in a large cohort of COVID-19 patients despite thromboprophylaxis: A retrospective study. <i>Thrombosis Research</i> , 2021, 199, 132-142.	1.7	29
16	From Biomarkers to Models in the Changing Landscape of Chronic Lymphocytic Leukemia: Evolve or Become Extinct. <i>Cancers</i> , 2021, 13, 1782.	3.7	10
17	The Evolving Landscape of Chronic Lymphocytic Leukemia on Diagnosis, Prognosis and Treatment. <i>Diagnostics</i> , 2021, 11, 853.	2.6	15
18	Pomalidomide, Cyclophosphamide, and Dexamethasone for the Treatment of Relapsed/Refractory Multiple Myeloma: Real-World Analysis of the Pethema-GEM Experience. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2021, 21, 413-420.	0.4	6

#	ARTICLE	IF	CITATIONS
19	Biological significance of monoallelic and biallelic BIRC3 loss in del(11q) chronic lymphocytic leukemia progression. <i>Blood Cancer Journal</i> , 2021, 11, 127.	6.2	12
20	COVID-19 in patients with CLL: improved survival outcomes and update on management strategies. <i>Blood</i> , 2021, 138, 1768-1773.	1.4	53
21	Real-World Characteristics and Outcome of Patients Treated With Single-Agent Ibrutinib for Chronic Lymphocytic Leukemia in Spain (IBRORS-LLC Study). <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2021, 21, e985-e999.	0.4	13
22	Treatment patterns and outcomes among nontransplant newly diagnosed multiple myeloma patients in Spain. <i>Future Oncology</i> , 2021, 17, 3465-3476.	2.4	1
23	Long-term efficacy and safety of CT-P10 or rituximab in untreated advanced follicular lymphoma: a randomized phase 3 study. <i>Blood Advances</i> , 2021, 5, 3354-3361.	5.2	6
24	Severe infections in patients with lymphoproliferative diseases treated with new targeted drugs: A multicentric real-world study. <i>Cancer Medicine</i> , 2021, 10, 7629-7640.	2.8	13
25	Restoration of the immune function as a complementary strategy to treat Chronic Lymphocytic Leukemia effectively. <i>Journal of Experimental and Clinical Cancer Research</i> , 2021, 40, 321.	8.6	15
26	COVID-19 severity and mortality in patients with CLL: an update of the international ERIC and Campus CLL study. <i>Leukemia</i> , 2021, 35, 3444-3454.	7.2	57
27	Severity of Covid-19 Clinical Outcomes and Mortality in Multiple Myeloma Patients over Year 1 of the Pandemic. <i>Blood</i> , 2021, 138, 2719-2719.	1.4	1
28	Use of eltrombopag for patients 65 years old or older with immune thrombocytopenia. <i>European Journal of Haematology</i> , 2020, 104, 259-270.	2.2	9
29	La realidad asistencial del tratamiento del mieloma múltiple de alto riesgo en España. <i>Medicina Clínica</i> , 2020, 154, 315-319.	0.6	0
30	Composite Lymphoma Containing Mantle Cell and Peripheral T-cell Lymphoma, Not Otherwise Specified: A Report of 2 Cases Treated With Up-front Autologous Stem Cell Transplantation. <i>Applied Immunohistochemistry and Molecular Morphology</i> , 2020, 28, e94-e98.	1.2	2
31	Impact of hematologic malignancy and type of cancer therapy on COVID-19 severity and mortality: lessons from a large population-based registry study. <i>Journal of Hematology and Oncology</i> , 2020, 13, 133.	17.0	171
32	Outcomes of COVID-19 in patients with CLL: a multicenter international experience. <i>Blood</i> , 2020, 136, 1134-1143.	1.4	248
33	Chronic lymphocytic leukemia patients with <i>IGH</i> translocations are characterized by a distinct genetic landscape with prognostic implications. <i>International Journal of Cancer</i> , 2020, 147, 2780-2792.	5.1	19
34	COVID-19 in patients with hematological malignancies: A retrospective case series. <i>International Journal of Laboratory Hematology</i> , 2020, 42, e256-e259.	1.3	19
35	Multiple myeloma and SARS-CoV-2 infection: clinical characteristics and prognostic factors of inpatient mortality. <i>Blood Cancer Journal</i> , 2020, 10, 103.	6.2	57
36	Clinical characteristics and outcome of SARS-CoV-2 infection in admitted patients with chronic lymphocytic leukemia from a single European country. <i>Experimental Hematology and Oncology</i> , 2020, 9, 37.	5.0	9

#	ARTICLE	IF	CITATIONS
37	COVID-19 severity and mortality in patients with chronic lymphocytic leukemia: a joint study by ERIC, the European Research Initiative on CLL, and CLL Campus. <i>Leukemia</i> , 2020, 34, 2354-2363.	7.2	198
38	Worldwide Examination of Patients with CLL Hospitalized for COVID-19. <i>Blood</i> , 2020, 136, 45-49.	1.4	2
39	DIFFERENCES IN EX-VIVO CHEMOSENSITIVITY TO ANTHRACYCLINES IN FIRST LINE ACUTE MYELOID LEUKEMIA. <i>Mediterranean Journal of Hematology and Infectious Diseases</i> , 2019, 11, e2019016.	1.3	3
40	DNA damage response-related alterations define the genetic background of patients with chronic lymphocytic leukemia and chromosomal gains. <i>Experimental Hematology</i> , 2019, 72, 9-13.	0.4	9
41	Ibrutinib for the treatment of relapsed/refractory mantle cell lymphoma: extended 3.5-year follow up from a pooled analysis. <i>Haematologica</i> , 2019, 104, e211-e214.	3.5	122
42	The International Prognostic Index for Patients with Chronic Lymphocytic Leukemia Has the Higher Value in Predicting Overall Outcome Compared with the Barcelona-Brno Biomarkers Only Prognostic Model and the MD Anderson Cancer Center Prognostic Index. <i>BioMed Research International</i> , 2018, 2018, 1-8.	1.9	18
43	Drug-to-drug interactions of tyrosine kinase inhibitors in chronic myeloid leukemia patients. Is it a real problem?. <i>Annals of Hematology</i> , 2018, 97, 2089-2098.	1.8	18
44	Alteraciones moleculares en leucemia mieloide aguda y sus implicaciones clínicas y terapéuticas. <i>Medicina Clínica</i> , 2018, 151, 362-367.	0.6	21
45	Risk of thrombosis according to need of phlebotomies in patients with polycythemia vera treated with hydroxyurea. <i>Haematologica</i> , 2017, 102, 103-109.	3.5	52
46	Genetic Heterogeneity in Chronic Lymphocytic Leukemia: What Can Conventional Cytogenetics Add?. <i>Acta Haematologica</i> , 2017, 138, 31-32.	1.4	4
47	Efficacy, pharmacokinetics, and safety of the biosimilar CT-P10 compared with rituximab in patients with previously untreated advanced-stage follicular lymphoma: a randomised, double-blind, parallel-group, non-inferiority phase 3 trial. <i>Lancet Haematology</i> , 2017, 4, e362-e373.	4.6	70
48	Linfomas con reordenamiento de MYC distintos del linfoma de Burkitt: comparación entre R-CHOP y la inmunoterapia tipo Burkitt. <i>Medicina Clínica</i> , 2017, 149, 339-342.	0.6	2
49	Efficacy and safety of eltrombopag in persistent and newly diagnosed ITP in clinical practice. <i>International Journal of Hematology</i> , 2017, 106, 508-516.	1.6	39
50	Eltrombopag safety and efficacy for primary chronic immune thrombocytopenia in clinical practice. <i>European Journal of Haematology</i> , 2016, 97, 297-302.	2.2	34
51	Real Life Long-Term Survival Analysis in Patients with Chronic Myeloid Leukemia Treated with Tkis in Spain. <i>Blood</i> , 2016, 128, 3074-3074.	1.4	0
52	Switching to second-generation tyrosine kinase inhibitor improves the response and outcome of frontline imatinib-treated patients with chronic myeloid leukemia with more than 10% of BCR-ABL/ABL ratio at 3 months. <i>Cancer Medicine</i> , 2015, 4, 995-1002.	2.8	8
53	Chronic Lymphocytic Leukemia: A Paradigm of Innate Immune Cross-Tolerance. <i>Journal of Immunology</i> , 2015, 194, 719-727.	0.8	33
54	Successful discontinuation of eltrombopag after complete remission in patients with primary immune thrombocytopenia. <i>American Journal of Hematology</i> , 2015, 90, E40-3.	4.1	121

#	ARTICLE	IF	CITATIONS
55	Do chronic myeloid leukemia patients with late "warning" responses benefit from "watch and wait" or switching therapy to a second generation tyrosine kinase inhibitor?. American Journal of Hematology, 2014, 89, E206-11.	4.1	6
56	Dose-intensive chemotherapy including rituximab in Burkitt's leukemia or lymphoma regardless of human immunodeficiency virus infection status. Cancer, 2013, 119, 1660-1668.	4.1	63
57	Lymphomas With MYC-Translocation Other Than Burkitt's Have An Aggressive Presentation and Poor Response To Immunochemotherapy: Study Of 34 Cases. Blood, 2013, 122, 5083-5083.	1.4	1
58	Primary laryngeal T/NK-cell lymphoma, nasal-type: an unusual location for an aggressive subtype of extranodal lymphoma. European Archives of Oto-Rhino-Laryngology, 2008, 265, 705-708.	1.6	21
59	Prognostic impact of highly active antiretroviral therapy in HIV-related Hodgkin's disease. Aids, 2002, 16, 1973-1976.	2.2	32
60	New Insights in Prognosis and Therapy of Chronic Lymphocytic Leukaemia. , 0, , .		0